Many dividend investors may be overlooking Pfizer's stock, and that could be a costly mistake.

Florida Attorney General James Uthmeier on Thursday filed a lawsuit against Pfizer and its CEO, Albert Bourla, accusing the ...

Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 fourth-quarter 2026 dividend on the company’s common stock, payable December 7, 2026, to holders of the Common ...

Ten consecutive earnings beats and a shrinking COVID hangover have Wall Street split on whether Pfizer deserves a breakout or ...

Vaxcyte is poised to capture significant share of a $3 billion to $6 billion market following the latest trial results, ...

A plague headline out of Siberia lifted vaccine stocks, and the agencies closest to the case have since described the risk as low. That reversal in sentiment lands hardest on Novavax (NASDAQ:NVAX), ...

Pfizer (PFE) currently faces dual concerns in the market about its growth prospects and dividend safety, causing its valuation to remain low. However, from the perspective of financial ...

The crowd is looking at the next couple of years. It should be looking five years into the future.

A legal filing in Florida accuses pharmaceutical giant Pfizer Inc. PFE and Chairman and CEO Albert Bourla of deceiving ...

If you've been looking for high-yield stocks, Pfizer (PFE-1.40%) may have crossed your radar screen. As shares of the pharma ...

Moderna stock has surged nearly 600% this year on a cancer vaccine trial result that almost no one outside the trial has ...